Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. has revised the terms of reference for its Nomination and Corporate Governance Committee as of December 12, 2025. This committee, established to oversee nomination and corporate governance matters, consists of at least three members, with a majority being independent non-executive directors, ensuring diversity and independence in its operations. The committee is chaired by the chairperson of the Board or an independent non-executive director and meets at least once a year to uphold governance standards.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a company incorporated in the Cayman Islands with limited liability, and it is listed on the Stock Exchange of Hong Kong. The company operates within the pharmaceutical industry, focusing on the development and commercialization of innovative therapies.
Average Trading Volume: 4,141,452
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$6.59B
See more data about 2105 stock on TipRanks’ Stock Analysis page.